GlassScriptPhysician profile
Frank G Talon
NPI 1558042317
$5,946.49
in general payments reported to CMS, 2019-2025
22 companies · $3,318 in 2025
The $3,318 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $409 · 2024: $2,219 · 2025: $3,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,946.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,761.80 | 2023-2025 | |
| Madrigal Pharmaceuticals | $718.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $518.48 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $501.36 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $372.49 | 2024-2025 | Epclusa, Livdelzi |
| Qol Medical, LLC | $368.10 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $324.94 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $252.75 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.05 | 2023-2025 | Xifaxan, Plenvu |
| Ipsen Biopharmaceuticals, INC | $186.34 | 2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $161.30 | 2023-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $152.08 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $95.33 | 2025 | Eohilia |
| Ironwood Pharmaceuticals, INC | $94.52 | 2024 | |
| Organon LLC | $61.84 | 2023-2024 | Hadlima |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $51.64 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $29.78 | 2023-2024 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.40 | 2024 | Cyltezo |
| Celltrion USA INC. | $21.98 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $18.80 | 2025 | Dupixent |
| Pfizer INC. | $16.47 | 2024 | |
| Janssen Pharmaceuticals, INC | $12.63 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Talon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.